Triheptanoin (Dojolvi)

A clinical trial has been running since 2014 for the treatment of Long Chain Fatty Acids, this trial drug is called Triheptanoin.

Ultragenyx has now announced that this drug has been FDA approved and has been given to patients on compassionate grounds.

Dojolvi is a highly purified, pharmaceutical-grade, odd-carbon medium-chain triglyceride consisting of three 7-carbon fatty acids on a glycerol backbone created via a multi-step chemical process. It is designed to provide medium-chain, odd-carbon fatty acids as an energy source and metabolite replacement for people with LC-FAOD.

Dojolvi is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD).

For more information please click on the download option.


Triheptanoin (Dojolvi) Approval Article

Here is an article about the recent clinical trial drug known as Triheptanoin (Dojolvi).

This is a very useful link.


Fatty Oxidation Disorder

Here is some information about a Fatty Oxidation Disorder that you may find useful

Here is a link of the full article

Meeting info Uncategorised

Upcoming Meeting

Hello Everyone

I would like to let you all know that Saturday 22nd May we are holding a video meeting for everyone with a Fatty Oxidation Disorder, this meeting will begin at 6pm UK time so please check your time difference if over seas.

These meetings are a great way to meet others with rare conditions.

Meeting details:
Time: 6pm UK time
Link details:

We look forward to seeing you all Saturday